Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05838183 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interstitial Lung Disease and Obstructive Sleep Apnea

StatusRecruiting
PhaseNot specified
SponsorDan Liu
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 31, 2025 to Dec 31, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v6
  2. Site contact updatedv5
  3. Re-verified, no change to tracked fieldsv4
  4. Primary completion date: Dec 31, 2023 to Aug 31, 2025
    • Study completion date: Dec 31, 2023 to Dec 31, 2025
    • Start date: Apr 1, 2023 to Sep 1, 2019
    • Site contact updated
    v3
  5. Primary endpoint revisedv2 Show 4 more changesShow less
    • Interventions: IL-17A,S100A8 (Diagnostic Test) to The relationship between imaging and ROSE and NGS (Diagnostic Test)
    • Eligibility criteria shortened, about 37 words
    • Secondary endpoints expanded, about 7 words
    • Study title revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Dan Liu
3 trials monitored
See all monitored trials
Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease. All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected ZNF331, Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively
Trial Details
NCT Number NCT05838183
Lead Sponsor Dan Liu
Conditions
(from sponsor)		 ILD OSA
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov